Billions of highly trained killers are flowing through your fingers right now ... a professor of regenerative medicine at the UC San Diego School of Medicine and co-founder and chief scientific ...

Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)NEW YORK, Feb. 18, 2025 ...

a company developing a novel gene therapy for retinal degenerative diseases, announced today that the FDA granted Regenerative Medicine Advanced Therapy (RMAT ... seen across a spectrum of patients -- ...

A regenerative medicine therapy is eligible for RMAT designation if it is intended to treat ... EXG-34217 is a dose of autologous CD34 + HSCs that have transiently expressed Zinc finger and SCAN ...